160 related articles for article (PubMed ID: 24167945)
21. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
22. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
Ceravolo R; Cossu G; Bandettini di Poggio M; Santoro L; Barone P; Zibetti M; Frosini D; Nicoletti V; Manganelli F; Iodice R; Picillo M; Merola A; Lopiano L; Paribello A; Manca D; Melis M; Marchese R; Borelli P; Mereu A; Contu P; Abbruzzese G; Bonuccelli U
Mov Disord; 2013 Sep; 28(10):1391-7. PubMed ID: 23836370
[TBL] [Abstract][Full Text] [Related]
23. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
[TBL] [Abstract][Full Text] [Related]
24. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
25. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
[TBL] [Abstract][Full Text] [Related]
26. Role of homocysteine in the treatment of Parkinson's disease.
Müller T
Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
[TBL] [Abstract][Full Text] [Related]
27. Motor complications, levodopa metabolism and progression of Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):847-55. PubMed ID: 21480824
[TBL] [Abstract][Full Text] [Related]
28. [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations].
Herrmann W; Lorenzl S; Obeid R
Fortschr Neurol Psychiatr; 2007 Sep; 75(9):515-27. PubMed ID: 17729191
[TBL] [Abstract][Full Text] [Related]
29. [Homocysteine and cognitive impairment in Parkinson's disease].
Martín-Fernández JJ; Carles-Díes R; Cañizares F; Parra S; Avilés F; Villegas I; Morsi-Hassan O; Fernández-Barreiro A; Herrero MT
Rev Neurol; 2010 Feb 1-15; 50(3):145-51. PubMed ID: 20146187
[TBL] [Abstract][Full Text] [Related]
30. Levodopa, homocysteine and Parkinson's disease: What's the problem?
Ahlskog JE
Parkinsonism Relat Disord; 2023 Apr; 109():105357. PubMed ID: 36922273
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
Mancini F; Comi C; Oggioni GD; Pacchetti C; Calandrella D; Coletti Moja M; Riboldazzi G; Tunesi S; Dal Fante M; Manfredi L; Lacerenza M; Cantello R; Antonini A
Parkinsonism Relat Disord; 2014 Jan; 20(1):27-31. PubMed ID: 24099722
[TBL] [Abstract][Full Text] [Related]
32. Hyperhomocysteinemia: Impact on Neurodegenerative Diseases.
Sharma M; Tiwari M; Tiwari RK
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):287-96. PubMed ID: 26036286
[TBL] [Abstract][Full Text] [Related]
33. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
34. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Di Rocco A; Werner P
Neurology; 2007 Apr; 68(17):1440; author reply 1440-1. PubMed ID: 17452598
[No Abstract] [Full Text] [Related]
35. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
Yasui K; Nakaso K; Kowa H; Takeshima T; Nakashima K
Acta Neurol Scand; 2003 Jul; 108(1):66-7. PubMed ID: 12807397
[No Abstract] [Full Text] [Related]
36. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
37. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
38. The effect of entacapone on homocysteine levels in Parkinson disease.
Ostrem JL; Kang GA; Subramanian I; Guarnieri M; Hubble J; Rabinowicz AL; Bronstein J
Neurology; 2005 Apr; 64(8):1482. PubMed ID: 15851757
[No Abstract] [Full Text] [Related]
39. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
40. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
Postuma RB; Lang AE
Neurology; 2004 Sep; 63(5):886-91. PubMed ID: 15365141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
